Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

Last updated: January 10, 2020
Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Overall Status: Active - Recruiting

Phase

2

Condition

Leukemia

Lymphocytic Leukemia, Acute

Treatment

N/A

Clinical Study ID

NCT03339700
INCMNSZ REF 2235
  • Ages 18-60
  • All Genders

Study Summary

The main purpose of the project is to evaluate the disease free survival and overall survival in patients diagnosed with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) adding gemcitabine to the standard institutional conditioning regimen based on two alkylating drugs, reduced busulfan and cyclophosphamide (reduced BUCY 2).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of acute lymphoblastic leukemia in 2nd complete remission or primaryrefractory disease, candidates to hematopoietic stem cell transplantation.

  • Hemoglobin ≥ 10 g/dl, Absolute Neutrophil Count ≥ 1 x 103/mm3, and Platelets ≥ 100,000 /µL

  • Eastern Cooperative Oncology Group status (ECOG) ≤2 oR Karnofsky ≥80%

  • Signed Informed Consent

  • Left ventricular ejection fraction (LVEF) >40%

  • Normal liver function enzyme tests

  • Preserved renal function

Exclusion

Exclusion Criteria:

  • Patients not willing to participate or to sign the informed consent

  • Patients who do not meet the inclusion criteria

Study Design

Total Participants: 15
Study Start date:
September 15, 2018
Estimated Completion Date:
September 30, 2021

Study Description

In the last decade, hematopoietic stem cell transplantation (HSCT) has become an efficient strategy for the treatment of high risk acute lymphoblastic leukemias. Lymphoid acute leukemias (ALL) are considered malignant clonal diseases of the hematopoietic stem cells, and represent a therapeutic challenge due to the high relapse rate and mortality using conventional chemotherapy regimens. Many studies have shown a decrease in relapse and an increase in overall survival with allogeneic HSCT, however, despite the fact that results in ALL have improved in the past years, achieving complete remission (CR) in approximately 75% of the patients, the relapse rate remains high and long term survival is lower than 50% depending on age and disease characteristics. On the other hand, it has been stated that relapse is higher when an allo-HSCT is performed in second CR, obtaining poorer results compared to performing HSCT in first CR, although better than chemotherapy alone (87% probability of relapse).

It is necessary to implement strategies that increase efficiency of pre transplant conditioning regimens in patients diagnosed with ALL undergoing an allo-HSCT in order to reduce relapse and increase overall survival. The hypothesis is that adding gemcitabine to the standard institutional conditioning regimen (reduced BUCY 2) in patients with ALL undergoing an allo-HSCT, the relapse free survival as well as the overall survival will improve, because it has been demonstrated in other malignant hematological diseases that gemcitabine plus two alkylating agents, facilitates synergism with busulfan and melphalan, inhibiting the DNA damage repair and causing a higher cytotoxic effect.

Connect with a study center

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    Mexico City, Distrito Federal 14080
    Mexico

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.